<DOC>
	<DOCNO>NCT00127634</DOCNO>
	<brief_summary>This phase 3 , open-label , randomize study evaluate safety efficacy Lilly/Alkermes inhale insulin system compare injected pre-meal insulin non-smoking patient type 1 diabetes . Patients treat 24 month 2-month follow-up period .</brief_summary>
	<brief_title>Study Human Insulin Inhalation Powder Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes Non smoker Normal lung function Significant pulmonary , hepatic , renal disease Severe congestive heart failure Active malignancy Systemic glucocorticoid therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>